非肌肉浸润性膀胱癌病理学的挑战：泌尿科医师与病理学家之间的对话。
Challenges in the pathology of non-muscle-invasive bladder cancer: a dialogue between the urologic surgeon and the pathologist.
机构信息
Cleveland Clinic Foundation, Cleveland, OH 44195, USA.
出版信息
Urology. 2013 Jun;81(6):1123-30. doi: 10.1016/j.urology.2013.01.027. Epub 2013 Mar 19.
Abstract
Approximately 70%-80% of urothelial carcinomas are detected at the stage of non-muscle-invasive bladder cancer (NMIBC). Initial management is often successful, but recurrence is common and leads to a long, burdensome, costly disease course. The quality and efficiency of care depends in part on accurate, clearly communicated descriptions of tumor characteristics. This review identifies current best practices, unmet needs, and key issues in the pathology of NMIBC for the practicing urologist. Reasonable and objective recommendations are provided with the goal of improving urologist-pathologist communication, the efficiency of healthcare utilization, and outcomes for patients with NMIBC.
摘要
大约 70%-80%的尿路上皮癌是在非肌肉浸润性膀胱癌（NMIBC）阶段被发现的。初始治疗通常是成功的，但复发很常见，导致疾病过程漫长、负担沉重且费用高昂。护理的质量和效率部分取决于对肿瘤特征的准确、清晰的描述。本综述确定了当前 NMIBC 病理学的最佳实践、未满足的需求和关键问题，以供临床泌尿科医生参考。提出了合理和客观的建议，目的是改善泌尿科医生与病理学家之间的沟通、医疗保健利用的效率以及 NMIBC 患者的预后。
相似文献
1
Challenges in the pathology of non-muscle-invasive bladder cancer: a dialogue between the urologic surgeon and the pathologist.非肌肉浸润性膀胱癌病理学的挑战：泌尿科医师与病理学家之间的对话。
Urology. 2013 Jun;81(6):1123-30. doi: 10.1016/j.urology.2013.01.027. Epub 2013 Mar 19.
2
EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013.EAU 指南：非肌层浸润性膀胱尿路上皮癌：2013 年更新版。
Eur Urol. 2013 Oct;64(4):639-53. doi: 10.1016/j.eururo.2013.06.003. Epub 2013 Jun 12.
3
EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.EAU 指南：非肌层浸润性膀胱尿路上皮癌：2016 年更新版。
Eur Urol. 2017 Mar;71(3):447-461. doi: 10.1016/j.eururo.2016.05.041. Epub 2016 Jun 17.
4
Surgeon Scorecards Improve Muscle Sampling on Transurethral Resection of Bladder Tumor and Recurrence Outcomes in Patients with Nonmuscle Invasive Bladder Cancer.外科医生评分卡可提高非肌肉浸润性膀胱癌患者经尿道膀胱肿瘤切除术的肌肉取样和复发结果。
J Urol. 2021 Mar;205(3):693-700. doi: 10.1097/JU.0000000000001372. Epub 2020 Oct 6.
5
6
Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.再次经尿道膀胱肿瘤切除术（re-cTURBT）作为pT1期高级别（HG）疾病复发和进展的风险指标是否有用？一项单中心经验。
Arch Ital Urol Androl. 2017 Dec 31;89(4):272-276. doi: 10.4081/aiua.2017.4.272.
7
Presence of Concomitant Non-muscle-invasive Bladder Cancer in Chinese Patients with Upper Tract Urothelial Carcinoma: Risk Factors, Characteristics, and Predictive Value.中国上尿路尿路上皮癌患者合并非肌层浸润性膀胱癌的情况：危险因素、特征及预测价值
Ann Surg Oncol. 2015 Aug;22(8):2789-98. doi: 10.1245/s10434-014-4302-5. Epub 2015 Jan 7.
8
Prognostic Performance and Reproducibility of the 1973 and 2004/2016 World Health Organization Grading Classification Systems in Non-muscle-invasive Bladder Cancer: A European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel Systematic Review.1973 年和 2004/2016 年世界卫生组织分级分类系统在非肌肉浸润性膀胱癌中的预后性能和可重复性：欧洲泌尿外科学会非肌肉浸润性膀胱癌指南小组系统评价。
Eur Urol. 2017 Nov;72(5):801-813. doi: 10.1016/j.eururo.2017.04.015. Epub 2017 Apr 28.
9
Enhanced Quality and Effectiveness of Transurethral Resection of Bladder Tumour in Non-muscle-invasive Bladder Cancer: A Multicentre Real-world Experience from Scotland's Quality Performance Indicators Programme.非肌层浸润性膀胱癌经尿道膀胱肿瘤切除术的质量与效果提升：来自苏格兰质量绩效指标计划的多中心真实世界经验
Eur Urol. 2020 Oct;78(4):520-530. doi: 10.1016/j.eururo.2020.06.051. Epub 2020 Jul 17.
10
Prognostic significance of non-muscle-invasive bladder tumor history in patients with upper urinary tract urothelial carcinoma.非肌层浸润性膀胱肿瘤史对上尿路尿路上皮癌患者的预后意义。
Urol Oncol. 2013 Nov;31(8):1615-20. doi: 10.1016/j.urolonc.2012.03.004. Epub 2012 Apr 21.
引用本文的文献
1
How do endoscopic bladder tumor resection techniques affect pathology practice? EAU Section of Uro-Technology (ESUT) and Uropathology (ESUP) survey.内镜下膀胱肿瘤切除技术如何影响病理学实践？欧洲泌尿外科学会泌尿技术分会（ESUT）和泌尿病理学分会（ESUP）调查。
World J Urol. 2023 Oct;41(10):2617-2625. doi: 10.1007/s00345-022-04022-2. Epub 2022 May 14.
2
Emerging Roles for Mammalian Target of Rapamycin (mTOR) Complexes in Bladder Cancer Progression and Therapy.雷帕霉素哺乳动物靶点（mTOR）复合物在膀胱癌进展和治疗中的新作用
Cancers (Basel). 2022 Mar 18;14(6):1555. doi: 10.3390/cancers14061555.
3
Bladder Cancer Sample Handling and Reporting: Pathologist's Point of View.膀胱癌样本的处理与报告：病理学家的观点
Front Surg. 2021 Dec 2;8:754741. doi: 10.3389/fsurg.2021.754741. eCollection 2021.
4
The rational and benefits of the second look transurethral resection of the bladder for T1 high grade bladder cancer.T1期高级别膀胱癌二期经尿道膀胱肿瘤切除术的合理性及益处
Transl Androl Urol. 2019 Feb;8(1):46-53. doi: 10.21037/tau.2018.10.19.
5
Renin-Angiotensin Inhibitors Decrease Recurrence after Transurethral Resection of Bladder Tumor in Patients with Nonmuscle Invasive Bladder Cancer.肾素 - 血管紧张素抑制剂可降低非肌层浸润性膀胱癌患者经尿道膀胱肿瘤切除术后的复发率。
J Urol. 2015 Nov;194(5):1214-9. doi: 10.1016/j.juro.2015.05.104. Epub 2015 Jul 11.
6
Impact of 2004 ISUP/WHO classification on bladder cancer grading.2004年国际泌尿病理学会/世界卫生组织分类对膀胱癌分级的影响。
World J Urol. 2015 Dec;33(12):1929-36. doi: 10.1007/s00345-015-1548-x. Epub 2015 Apr 2.
7
Kava chalcone, flavokawain A, inhibits urothelial tumorigenesis in the UPII-SV40T transgenic mouse model.卡瓦胡椒查尔酮、黄烷酮 A 抑制 UPII-SV40T 转基因小鼠模型中的尿路上皮肿瘤发生。
Cancer Prev Res (Phila). 2013 Dec;6(12):1365-75. doi: 10.1158/1940-6207.CAPR-13-0219. Epub 2013 Oct 11.
本文引用的文献
1
A contemporary update on pathology standards for bladder cancer: transurethral resection and radical cystectomy specimens.膀胱癌病理标准的当代更新：经尿道切除和根治性膀胱切除术标本。
Eur Urol. 2013 Feb;63(2):321-32. doi: 10.1016/j.eururo.2012.10.008. Epub 2012 Oct 12.
2
ICUD-EAU International Consultation on Bladder Cancer 2012: Pathology.2012 年国际膀胱癌咨询委员会-欧洲泌尿外科协会：病理学。
Eur Urol. 2013 Jan;63(1):16-35. doi: 10.1016/j.eururo.2012.09.063. Epub 2012 Oct 5.
3
Voice recognition technology implementation in surgical pathology: advantages and limitations.语音识别技术在外科病理学中的应用：优势与局限性。
Arch Pathol Lab Med. 2011 Nov;135(11):1476-81. doi: 10.5858/arpa.2010-0714-OA.
4
A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group.国际膀胱癌组织对非肌肉浸润性膀胱癌管理的现行指南和最佳实践建议综述。
J Urol. 2011 Dec;186(6):2158-67. doi: 10.1016/j.juro.2011.07.076. Epub 2011 Oct 19.
5
Compliance with guidelines for patients with bladder cancer: variation in the delivery of care.膀胱癌患者指南依从性：护理提供的差异。
Cancer. 2011 Dec 1;117(23):5392-401. doi: 10.1002/cncr.26198. Epub 2011 Jul 11.
6
Recent advances in standards for Collaborative Digital Anatomic Pathology.协作式数字解剖病理学标准的最新进展。
Diagn Pathol. 2011 Mar 30;6 Suppl 1(Suppl 1):S17. doi: 10.1186/1746-1596-6-S1-S17.
7
EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update.EAU 指南：非肌层浸润性膀胱尿路上皮癌，2011 年更新版。
Eur Urol. 2011 Jun;59(6):997-1008. doi: 10.1016/j.eururo.2011.03.017. Epub 2011 Mar 22.
8
Handling and reporting of transurethral resection specimens of the bladder in Europe: a web-based survey by the European Network of Uropathology (ENUP).欧洲经尿道膀胱切除术标本的处理和报告：欧洲泌尿病理网络（ENUP）的一项基于网络的调查。
Histopathology. 2011 Mar;58(4):579-85. doi: 10.1111/j.1365-2559.2011.03784.x. Epub 2011 Feb 23.
9
Electronic capture and communication of synoptic cancer data elements from pathology reports: results of the Reporting Pathology Protocols 2 (RPP2) project.从病理报告中电子捕获和交流概要性癌症数据元素：报告病理协议2（RPP2）项目的结果
J Registry Manag. 2009 Winter;36(4):117-24; quiz 163-5.
10
Clinical impact of bladder biopsies with TUR-BT according to cytology results in patients with bladder cancer: a case control study.根据膀胱癌患者膀胱活检与 TUR-BT 的细胞学结果的临床影响：一项病例对照研究。
BMC Urol. 2010 Jun 30;10:12. doi: 10.1186/1471-2490-10-12.
Zotero 插件